Shares of Lupin Ltd ended 3% greater after hitting a day’s excessive of Rs 1,953.80 on third September, following the corporate’s announcement that it has obtained approval from america Meals and Drug Administration (USFDA) for its Abbreviated New Drug Utility (ANDA) for Risperidone Injectable.
Lupin obtained USFDA approval for Risperidone extended-release injectable suspension in single-dose vials of 25 mg, 37.5 mg, and 50 mg. The drug is the bioequivalent of Risperdal Consta and is used to deal with schizophrenia and bipolar dysfunction.
That is Lupin’s first product developed utilizing Nanomi B.V.’s expertise and comes with 180 days of CGT exclusivity. Nanomi, a Lupin subsidiary, focuses on creating progressive long-acting injectable medicines.
CEO Vinita Gupta mentioned the corporate will proceed to leverage the Nanomi platform to construct novel long-acting injectables that tackle unmet affected person wants.
Risperidone extended-release injectable suspension had estimated annual US gross sales of $190 million as of July 2025, in keeping with IQVIA.
At 3:30 PM, shares of Lupin ended 3.30% greater at Rs 1,952 on NSE.
Prepared to take a position like a professional? Unicorn Indicators app equips you with 100+ Free instruments and data you have to succeed. Obtain the Unicorn Indicators app and achieve entry to every day inventory lists and insightful market evaluation and way more!
